- Research article
- Open Access
Molecular cloning and functional characterization of an ATP-binding cassette transporter OtrC from Streptomyces rimosus
© Yu et al.; licensee BioMed Central Ltd. 2012
- Received: 31 March 2012
- Accepted: 11 August 2012
- Published: 20 August 2012
The otrC gene of Streptomyces rimosus was previously annotated as an oxytetracycline (OTC) resistance protein. However, the amino acid sequence analysis of OtrC shows that it is a putative ATP-binding cassette (ABC) transporter with multidrug resistance function. To our knowledge, none of the ABC transporters in S. rimosus have yet been characterized. In this study, we aimed to characterize the multidrug exporter function of OtrC and evaluate its relevancy to OTC production.
In order to investigate OtrC’s function, otrC is cloned and expressed in E. coli The exporter function of OtrC was identified by ATPase activity determination and ethidium bromide efflux assays. Also, the susceptibilities of OtrC-overexpressing cells to several structurally unrelated drugs were compared with those of OtrC-non-expressing cells by minimal inhibitory concentration (MIC) assays, indicating that OtrC functions as a drug exporter with a broad range of drug specificities. The OTC production was enhanced by 1.6-fold in M4018 (P = 0.000877) and 1.4-fold in SR16 (P = 0.00973) duplication mutants, while it decreased to 80% in disruption mutants (P = 0.0182 and 0.0124 in M4018 and SR16, respectively).
The results suggest that OtrC is an ABC transporter with multidrug resistance function, and plays an important role in self-protection by drug efflux mechanisms. This is the first report of such a protein in S. rimosus, and otrC could be a valuable target for genetic manipulation to improve the production of industrial antibiotics.
- Streptomyces rimosus
- ATP-binding cassette transporter
- ATP hydrolysis
- Multidrug resistance
Clinical multidrug resistance (MDR) to bactericidal antibiotics is driving research into the underlying mechanisms of resistance and the discovery of novel drugs. In the past decade, numerous resistance proteins have identified, including the ubiquitous ATP-binding cassette (ABC) family of multidrug transporters [1–6]. These integral membrane proteins mediate the active extrusion of antibiotics and toxic compounds from cells. Recent crystal structure analyses revealed that some ABC-type multidrug proteins, such as MsbA from E. coli, Vibrio cholera, and Salmonella typhimurium[5–7] and BtuCD from E. coli, also mediate the import of substrates by altering the conformation of the transmembrane helices (TMs) from an ‘outward-facing’ state to an ‘inward-facing’ state . The ABC transporters represent 2% of gene products in bacteria and play a critical role in their adaptation to the environment . Some are involved in resistance to chemotherapy and, therefore, applied research has increasingly focused on the elucidation of the transportation mechanism of these proteins . Furthermore, the self-protection afforded by the antibiotic producers is dependent on its endogenous drug resistance proteins. Therefore, these resistance proteins may also represent targets for antibiotic production improvement strategies [12, 13].
Streptomyces rimosus, well known as an oxytetracycline (OTC) producer, has been investigated at the genetic level over many years, although only two antibiotic pump genes have been discovered to date: the OTC resistance gene, otrB and a putative ABC transporter gene, otrC, which has been isolated, sequenced and deposited in GenBank (AY509111.1). The two open read frames (orf) of the otrC gene encode a putative ABC transporter ATP-binding subunit and a putative transmembrane subunit. OtrC was considered to be a putative ABC transporter with an OTC resistance function based on its amino acid sequences, although no evidence in support of this has been reported to date. Generally, the location of resistance genes in the chromosome is close to the corresponding antibiotic biosynthesis clusters. In the case of OTC, the OTC cluster in S. rimosus is flanked by the resistance genes, otrA and otrB, while otrC is distant from the OTC cluster (data not published). We hypothesize that otrC plays a role as the MDR transporter in OTC resistance. Here, we present evidence that otrC encodes a protein with ATPase and multidrug efflux activities and therefore may represent a manipulation target for strategies to improve of OTC production in S. rimosus.
Conserved motifs analysis and model prediction of otrC
The otrC gene contains two open reading frames (ORFs), which encode a putative ATP-binding subunit (OtrC-ORF1) of 38 kDa and a putative transmembrane subunit (OtrC-ORF2) of 30 kDa. A NCBI BLAST search of the amino acid sequence of the OtrC protein identified a number of similar proteins, the majority of which were ABC components of doxorubicin or MDR ABC transporters from various phyla.
The prediction of the secondary structure of OtrC-ORF2 by the PROF method using the PredictProtein program (http://www.predictprotein.org) indicated the presence of a N-terminal hydrophobic domain with six putative α-helical transmembrane segments and cytoplasmic facing N and C termini. The reported canonical ABC systems display a modular architecture composed of two nucleotide-binding domains/subunits and two transmembrane domains/subunits. Therefore, it can be concluded that the OtrC system is a tetrameric complex composed of two homodimeric constituents, similar to that of many other bacterial ABC transporters .
Functional characterization of OtrC
Effect of OtrC expression on drug susceptibility
In order to identify the MDR function of OtrC, the OtrC-overexpressing and non-expressing mutants of the S. rimosus M4018 strain were constructed and identified as described in the Materials and Methods (Additional file 1: Figures S3 and S4).
Susceptibilities of E. coli mutants to several drugs
Susceptibilities of S. rimosus mutants to several drugs
A clear difference in drug sensitivity to these drugs was also found in S. rimosus mutants M4018/pSEC and M4018/pKCΔotrC with respect to the control strain M4018/pSET152. The overexpression of OtrC in M4018/pSEC resulted in significantly elevated MICs to ampicillin (3-fold), OTC (1.7-fold), doxorubicin (2-fold), EB (2-fold) and ofloxacin (20-fold). Furthermore, the OtrC overexpressing mutant survived with 500 μg/ml vancomycin, while the growth of M4018/pSET152 was completely inhibited by vancomycin (Table 2). The MICs for ampicillin and doxorubicin in the OtrC-disrupting mutant M4018/pKCΔotrC were decreased by 20%, compared to a decrease of 67% for OTC; however, the disruption of OtrC had no effect on EB and vancomycin sensitivity (Table 2). Neither the OtrC-overexpressing mutant nor the OtrC-disrupting mutant showed any alternation in the sensitivity to rifampicin, erythromycin and streptomycin (Table 1), which was in agreement with the results of drug susceptibility assays in OtrC-overexpressing E. coli cells.
The otrC overexpressing cells showed a significantly enhanced MIC to ampicillin, OTC, doxorubicin, EB, ofloxacin and vancomycin, which indicated that OtrC functions as a drug exporter with a broad range of drug specificities.
OtrC expression affects OTC production in S. rimosus
The OTC production profile in SR16 mutants showed that the OTC production of the OtrC knock-in mutant SR16/pSEC reached a peak of 1,384.1 mg/L at 72 h, which was 1.4-fold greater than that of SR16/pSET152 at 96 h. In contrast, the production of OTC was markedly reduced in the disrupted mutant SR16/pKCΔotrC. It yielded an OTC production rate of 784.2 mg/L at 168 h, which was approximately 80% of the peak production of SR16/pSET152 (Figure 6B). These results were in agreement with the above-mentioned conclusion that OtrC expression efficiently affects OTC production in S. rimosus.
The bacterial ATP-binding cassette (ABC) family of multidrug transporters contains very important resistance proteins that have evolved over a long period. In the present study, we characterized the function of OtrC, a putative ABC transporter, from S. rimosus and report that OtrC has major effects on the overproduction of OTC in S. rimosus.
The multidrug exporter function of OtrC from S. rimosus
OtrC-ORF2 contains the G−2…R4 conserved motif, but does not possess the EAA conserved motif (Figure 2). The former might be involved in drug export function, and the latter was identified to be involved in import function . To verify the function of OtrC as a drug transporter in cells, the E. coli cells that overexpressed OtrC were given glucose, which resulted in the extrusion of EB rather than its uptake as was expected (Figure 5). Furthermore, when the ABC transporter inhibitor orthovanadate was added, EB extrusion was not observed in the OtrC-expressing cells supplemented with ATP. This indicated that OtrC is responsible for the EB export activity in OtrC-expressing E. coli transformant. Hence, the drug resistance mechanism of OtrC could be based on ATP hydrolysis coupled with its transport ability.
The OtrC-expressing E. coli transformant showed significantly enhanced susceptibilities to ampicillin, doxorubicin, OTC, EB, vancomycin and ofloxacin (Figure 8A). However, the MICs of S. rimosus mutants to ampicillin, OTC, doxorubicin and ofloxacin were markedly amplified compared with controls (Figure 8B), which suggested that OtrC could play an important role in the self-protection mechanisms of S. rimosus. Interestingly, the MIC of M4018/pSEC to vancomycin was 500 μg/ml, and the growth of M4018/pKCΔotrC and M4018/pSET152 was completely inhibited under these conditions. This implies that OtrC acts as an efficient vancomycin efflux pump. Additionally, the significantly enhanced vancomycin resistance activity in S. rimosus M4018/pSEC might be attributed to the strong constitutive ermE* promoter, which results in the overexpression of OtrC during the early growth phase.
Effect of OtrC expression on OTC production in S. rimosus
The M4018 strain showed a stable production of OTC. In contrast, the SR16 mutants showed an obvious drop of OTC production after 3 days, which was probably due to the instability of SR16 (Figure 7). A red pigment was observed during SR16 fermentation (date not published), which, to our knowledge, has not been previously described in S. rimosus. We speculate that another competitive secondary metabolic pathway was activated in SR16 during the traditional mutation.
The real-time qRT-PCR analysis showed that OtrC overexpression could lead to a significant OTC production improvement by secreting OTC out of cells in both the M4018 S. rimosus strain and an industrial overproducer, SR16. Hence, it is reasonable to suggest that otrC could be a valuable target for genetic manipulation, such as introducing extra copies of the ABC transporter [12, 13], overexpressing the pathway genes with the use of transcription regulators [20–22] and the replacement of heterologous promoters [23, 24], in order to yield the overproduction of OTC.
OtrC is a putative ABC-type transporter in S. rimosus, although it has been considered to be an OTC resistance protein. However, the drug resistance function and mechanism of OtrC have not been studied previously. In this study, the alignment of the amino acid sequence of OtrC suggested that it could belong to an ABC superfamily and could act as an ATP-binding drug exporter, which was further identified by ATPase activity determination and EB efflux assays in this study. The results of the drug susceptibility tests showed that OtrC confers a functional resistance toward a broad range of structurally unrelated drugs. Hence, OtrC is a multidrug resistance protein based on an ATP hydrolysis-dependent active efflux mechanism. It is the first reported multidrug resistance ABC transporter in S. rimosus.
The further investigation of mutations of conserved amino acid residues that inhibit the OtrC pump could be valuable for controlling drug resistance in clinically important pathogens. Improvements in OTC production were successfully made by introducing an extra copy of otrC into the high-performance SR16 strain, while the disruption mutant displayed a decreased OTC yield. This highlights the potential value of OtrC in OTC industrial production. Future studies on the OTC efflux activity of OtrC and the effects of OtrC overexpression in S. rimosus will contribute to improvements in OTC production.
Bacterial strains, plasmids, antibiotics and antibodies
The bacterial strains used in this study were E. coli DH5α, ET12567 (pUZ8002) , BL21 (DE3), S. rimosus M4018 (a typical strain, gift from Prof. Iain S Hunter, University of Strathclyde, UK), and SR16 (an industrial overproducer obtained by traditional strain improvement, Shanxi Tongxing Antibiotic Company, China).
The plasmids used in this study included pMD19-T, pSET152, pKC1139, pET28a and pSEC (otrC in pSET152), pKCΔotrC (for otrC disruption, reconstructed by pKC1139), pETC02 (otrC in pET28a). E. coli strains were screened using a LB plate with 100 μg·ml-1 ampicillin, 50 μg·ml-1 apramycin, 25 μg·ml-1 kanamycin or 34 μg·ml-1 chloramphenicol when appropriate. S. rimosus mutants were screened by TSB plates with 500 μg·ml-1apramycin or 500 μg·ml-1 kanamycin.
Different concentration of ampicillin, oxytetracycline, doxorubicin, ethidium bromide, vancomycin, ofloxacin, rifampicin, erythromycin and streptomycin were used for the MDR assay with OtrC. His-tag mouse and peroxidase-conjugated goat anti-mouse IgG (SAB, USA) antibodies were employed for Western blotting analyses.
Media and growth conditions
Escherichia coli strains were cultured in Luria-Bertani (LB) medium (1.0% tryptone, 1.0% NaCl, 0.5% yeast extract) with appropriate antibiotics when necessary. S. rimosus strains were grown in tryptone soya broth (TSB) medium (3% tryptone soya broth, Oxoid) for genomic DNA extraction and mycelium growth, adding appropriate antibiotics, where needed. The mannitol soya flour (MS) medium (2% mannitol, 2% soya flour and 2% agar) was used to grow spores . The seed cultures were obtained by inoculating spores into glucose yeast casein hydrolysate and sucrose (GYCS) medium (1% glucose, 0.05% yeast extract, 1.5% casein hydrolysate, 0.28% sucrose, 0.01% CaCO3). Soluble starch and corn steep liquor (SC) medium  (2% soluble starch, 1% corn steep liquor, 0.6 (NH4)2SO4, 0.8% CaCO3, 0.5% NaCl, 0.2% soy bean oil, pH 6.8 to 7.2).
OtrC expression in E. coli
For OtrC heterologous expression in E. coli, the genomic DNA of M4018 was used as the template. The following primers, orf1F (5’CGCCATATGATGAC GCGAAAGACGATATCCA3’) and orf1R (5’CGCGGATCCTCATGCCGGAACCTCCTCG3’), were used to amplify the otrC open read frame 1 (orf1), which was introduced into the NdeI and BamHI sites (underlined); primers orf2F (5’CGCGGATCC GAAGGAGATATACCATGAGTGCCGCGACGGT3’) and orf2R (5’ATTTGCGGCCGCGGTCTTCTTGCGGAACTTGGC 3’) were used to amplify otrCorf2 which was introduced into the BamHI and NotI sites (underlined), and the optimized RBS sites of the T7 promoter (bold) was introduced towards the 5’ end. The amplified fragments (orf1, 1,074 bp and orf2, 870 bp) were subcloned into T-vector for sequencing, and then digested by restriction enzymes and cloned into the pET28a vector under the T7 promoter to construct the recombinant plasmid, pET28a-otrCorf1-otrCorf2 (pETC02).
After pETC02 was introduced into the E. coli BL21 (DE3) strain, for OtrC expression, the E. coli transformant (E.coli/pETC02) was cultured in LB medium with 50 μg/ml kanamycin. The growth of the cultures was monitored by recording the optical density at 600 nm (OD600); when it reached at 0.6, cells were induced by isopropyl beta-D-thiogalactopyranoside (IPTG) at a final concentration of 1 mM at 30°C, at 170 rpm for 10 h. The E. coli/pET28 transformant was cultured and induced under the same conditions and used as a negative control.
One-milliliter cell suspensions were centrifuged at 12,000 rpm for 10 min at 4°C, and washed with deionized water, then resuspended in 100 μl Tris–HCl (500 mM pH 7.0) buffer, and the cell disruption was performed by ultrasonic waves. The cell disruption suspension was centrifuged at 12,000 rpm for 15 min at 4°C to remove the cell debris, and the total membrane fractions were then harvested by centrifugation at 125,000 rpm, at 4°C for 1 h. The total protein sample and the membrane fractions were then analyzed by 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting following standard procedures .
ATPase assay of OtrC
For the ATPase assay, E. coli transformants were cultured in LB with 50 μg/ml kanamycin and induced with IPTG, as described above. A cell suspension sample of 1.5 ml with OD600 = 0.6 was obtained, and cells were collected by centrifugation at 10,000 rpm for 1 min. Cells were then washed with deionized water twice. Cell walls were digested by incubation for 1 h at 30°C with 10 mg/ml lysozyme (BBI, UK), after which DNase (100 μg/ml, TaKaRa, Japan) and 10 mM MgSO4 were then added. After a 10-min incubation, the suspension was centrifuged at 16,000 rpm for 15 min at 4°C to remove the cellular debris, and the membrane vesicles were then harvested by centrifugation at 125,000 rpm at 4°C for 1 h, and resuspended in 1.5 ml buffer A (50 mM Hepes pH 8.0, 250 mM NaCl, 10% glycerol [v/v]), and used as the protein sample in immediate assays for ATPase activity .
The malachite green assay was used to determine the specific ATPase activity of OtrC by measuring the release of inorganic phosphate. Briefly, 2 mM ATP was added into a 200 μl protein sample, 25-μl aliquots were transferred into 175 μl of 10 mM sulfuric acid to stop the reaction for 20 min. Subsequently, 50 μl of fresh malachite green/molybdate solution was added, and the absorbance at 650 nm was measured after incubation for 10–15 min [1, 28].
The malachite green/molybdate solution was freshly prepared and it contained malachite green solutions 1 (0.122% [w/v] malachite green, 20% [v/v] sulfuric acid), solutions 2 (7.5% [w/v] ammonium molybdate) and solutions 3 (11% [v/v] Tween 20) at a ratio of 50:12.5:1 .
Efflux assay of OtrC
The E. coli/pETC02 was cultured in LB with 50 μg/ml kanamycin and induced with IPTG. Subsequently, the cells were collected by centrifugation at 10,000 rpm at 4°C for 10 min, before being washed with 1 volume 50 mM KPi (pH 7.0) containing 5 mM MgSO4. The washed cell suspensions (OD600 = 0.5) were incubated for 10 min at 30°C in the presence of 20 μM ethidium bromide (EB). The EB efflux was initiated by the addition of 25 mM glucose, and the cell suspension was used to monitor the fluorescence of DNA-EB complex by a fluorimeter (Cary Eclipse, Australia) at 30°C using excitation and emission wavelengths of 500 and 580 nm, respectively, and slit widths of 5 and 10 nm, respectively .
To study the effect of ABC inhibitor Ortho-vanadate on the accumulation of EB in OtrC expressing and non-expressing E. coli cells , cells were cultured, induced, collected and washed as described above. Washed cells (OD600 = 0.5) were incubated for 10 min at 30°C in the presence or absence of 0.5 mM orthovanadate, followed by the addition of 20 μM ethidium bromide (EB) along with 2 mM Mg-ATP, and the fluorescence of EB was measured at 30°C as described above.
OtrC knock-in and disruption in S. rimosus
The ermE*p promoter region was amplified by using E*pf (5’CCGGAATTGTACCAGCCCGACCCGAG3’) and E*pr (5’ CGCGGATCCGTGGAGTGGTTCTGTATCCTACCAA 3’) as the primers to amplify a 306 bp fragment encompassing the EcoRI and BamHI cloning sites. The entire otrC gene (1,895 bp) encompassing the BamHI and XbaI sites were amplified using genomic DNA of M4018 as templates and otrCf (5’ CGCGGATCC CCTCTTACGAGNAAGTCATGAAGTTCCGCCGAATGNA 3’,) and otrCr (5’ TGCTCTAGATCAGGTCTTCTTGCGG AACTT3’) primers, where the natural RBS sequence of otrC was introduced into primer otrCf (bold). The fragments were cloned into a pMD19-T vector for sequencing, and the fragments were digested by the restriction enzymes after identification and inserted into a pSET152 vector to obtain the recombinant plasmid, pSET152-ermE*p-otrC (pSEC). This was identified by enzyme digesting and sequencing. Plasmid pSEC was introduced into E. coli ET12567 (pUZ8002) for demethylation and then introduced into the chromosomes of M4018 and SR16 by electroporation following standard procedures to generate the M4018/pSEC and SR16/pSEC mutant strains. The empty plasmid, pSET152, was introduced into M4018 and SR16 to construct M4018/pSET152 and SR16/pSET152, respectively, which were used as controls.
For the disruption of otrC, the CZ1 and CZ2 fragments were amplified by PCR using two sets of primer pairs: CZ1f (5’CCGGAATTCTGCCTGCCCGCCGTC3’) and CZ1r (5’ CCGGATATCTCCTCGTGGTCGGCGGT 3’), CZ2f (5’ CGCGGATCCCGGCGTGGTCAACGTC 3’) and CZ2r (5’TGCTCTAGACCCTGTCCGTTCATCNNN 3’), respectively. The kanamycin resistance cassette (Kanr) was amplified by PCR using the primer pairs kanf (5’ CCGGATATCTACAAGGGGTGTTATGAGCC 3’) and kanr (5’ CGCGGATCCTTAGAAAAACTCATCGAGCAT 3’). The final PCR products (CZ 1 : 993 bp, CZ 2 : 992 bp, Kanr: 832 bp) were cloned into the pMD19-T vector, and used for sequencing to confirm the correct amplification. Fragments CZ1 and CZ2 were used as the left bridge and the right bridge, respectively. Three resulting DNA fragments were digested by the restriction enzymes and inserted into the EcoRV and XbaI sites of the pKC1139 vector to generate pKC1139-CZ1-Kanr-CZ2 (pKCΔotrC). The recombinant plasmid was demethylated and introduced into either M4018 or SR16. The screening of the otrC disruption mutants M4018/pKCΔotrC and SR16/pKCΔotrC followed standard procedures . Confirmation of the otrC disruption was performed by the PCR amplification of kanr using genomic DNA of the mutants as a template.
Effect of OtrC expression on drug susceptibility
E.coli/pETC02 was grown in LB liquid medium with 50 μg/ml kanamycin, IPTG (1 mM) and different concentrations of drugs at 37°C, 170 rpm for 12 h, and then resuspended in 1 volume of fresh LB. Then, 50 μl cell suspension was spread immediately on the LB plates with 50 μg/ml kanamycin and 1 mM IPTG and different concentration of drugs, the plates were cultured at 37°C for 12 h to determine the minimal inhibitory concentrations (MICs). Experiments were performed in triplicate using E. coli/pET28a as the negative control.
S. rimosus mutants M4018/pSEC and M4018/pKCΔotrC were grown in TSB adding different concentrations of tested drugs with M4018/pSET152 at 28°C and 220 rpm; after 30 h growth, cells were collected by centrifugation and resuspended in 1 volume of TSB. Then, 50 μl of fresh mycelium suspension was spread immediately on the TSB plates with different concentration of tested drugs. The MICs were measured after incubation for 3 d at 28°C, and experiments were performed in triplicate.
Effect of OtrC expression on OTC production in S .rimosus
The mutants of M4018 and SR16 were cultured on the MS plates at 28°C for 3–5 d along with the parental strains; spores were collected and inoculated into GYCS medium to a final concentration of 1 × 106 spores per ml, after they were cultured at 28°C on a rotary shaker (260 rpm) for 72 h as the seed culture. For an assessment of OTC production, 1% seed culture was transferred into SC medium and cultured at 30°C on a rotary shaker (260 rpm) for 7 d. The OTC productivity of S. rimosus strains were measured by high performance liquid chromatography analysis (HPLC). Then, 1 ml culture samples were centrifuged at 12,000 rpm for 10 min after the pH was adjusted to pH 1.5-1.7 using 9 mol/L HCl. The supernatants were filtered through a 0.22-μm filter (Millipore, Bedford, MA) and 10 μl samples were injected for analysis. Agilent 1100 HPLC system equipped with a 5-μm C18 (Kromasil, Sweden) column (4.6 by 200 nm) was employed for the HPLC analysis. The mixture of 60% H2O, 10% methanol, 20% acetonitrile and 10% phosphoric acid (2 mM) was used for the mobile phase and applied with a constant flow rate of 0.8 ml min-1 over 10 min. The OTC detection wavelength was 350 nm .
qRT-PCR analysis of transcription levels
The transcription level of the otrC gene was analyzed by qRT-PCR as described previously . S. rimosus cells were collected at different developmental stages during fermentation. Fresh tissues were used for total RNA extraction immediately using the AxyPrepTM multisource total RNA miniprep kit (Axygen, USA). The genomic DNA was removed by DNase I digestion, and the purity of the RNA samples was measured as the ratio of RNA concentration (ng/μl) to protein concentration (ng/μl) by QubitTM RNA Assay Kits and QubitTM Protein Assay Kits (Invitrogen, CA, USA), using the Qubit® 2.0 fluorometer (Invitrogen), according to the instructions provided by the manufacturer. RNA samples (RNA:protein ratio, 1.8-2.0) were selected and examined by 3% agarose gel electrophoresis to check their integrity prior to qRT-PCR analysis [32, 33]. First strand cDNA synthesis was performed with a reverse transcription kit (TaKaRa, Japan) according to the manufacturer’s instructions. Standard curve was consisting of a 10-fold serial dilution series of five points which was prepared from cDNA samples (35 ng/μl) and each dilution was tested under a range of temperatures around the calculated Tm of the primers used in the experiments; untranscribed RNA samples were used as negative controls. The Cq values were determined for the optimization of qRT-PCR conditions.
qRT-PCR was assessed using SYBR® GC Premix Ex TaqTM kits (TaKaRa, Japan) and a CFX96TM 168 real-time PCR detection system (Bio-Rad, USA). The total 25 μl reaction volume contained 1 μl DNA, 0.2 μM forward primer, 0.2 μM reverse primer, and 1× SYBR® Premix Ex TaqTM, and the reaction conditions were as follows: 95°C for 30 s, and 40 cycles of 95°C for 5 s, 55-61°C for 30 s and 72°C for 30 s. Analysis of the melting curve was performed over a range of 55°C to 95°C for 5 s at the end of the PCR cycles. Three housekeeping genes, 16S rRNA, hrdB and G6PDH (zwf1) were used as reference genes to normalize the data [32, 34]. The optimized Tm and cDNA concentration of each gene were used for qRT-PCR analysis. The primers for qRT-PCR were as follows: QotrCf (GTCACACGAGCGCCCTGGT) and QotrCr (CGCCGCCGAAGACGTACAC) were used for otrC transcriptional level analysis; QhrdBf (CTCTGTCATGGCGCTCA) and QhrdBr (ACGTTCTTCCACTGAGTGG) for the reference gene hrdB; Q16Sf (AGACACGGCCCAGACTC) and Q16Sr (CTGCTGAAAGAGGTTTACAAC) for 16S rRNA; Qzwff (ACTGGGCCAGAACGCCCT) and Qzwfr (AGTCCATCGAGACGTCCCGTA) for zwf1.
This work was supported by the National Basic Research Program of China (973 Project) (No. 2011CB200904, 2012CB721006), and a grant from the National High Technology Research and Development Program of China (863 Program) (No. 2012AA021201), and the Fundamental Research Funds for the Central Universities (ECUST).
- Gustot A, Smriti , Ruysschaert JM, McHaourab H, Govaerts C: Lipid composition regulates the orientation of transmembrane helices in HorA, an ABC multidrug transporter. J Biol Chem. 2010, 285 (19): 14144-14151. 10.1074/jbc.M109.079673.View ArticleGoogle Scholar
- Rodriguez-Garcia A, Santamarta I, Perez-Redondo R, Martin JF, Liras P: Characterization of a two-gene operon epeRA involved in multidrug resistance in Streptomyces clavuligerus. Res Microbiol. 2006, 157 (6): 559-568. 10.1016/j.resmic.2005.12.008.View ArticleGoogle Scholar
- Oliveira AS, Baptista AM, Soares CM: Conformational changes induced by ATP hydrolysis in an ABC transporter: a molecular dynamics study of the Sav 1866 exporter. Proteins. 2011, 79 (6): 1977-1990. 10.1002/prot.23023.View ArticleGoogle Scholar
- Choudhuri BS, Bhakta S, Barik R, Basu J, Kundu M, Chakrabarti P: Overexpression and functional characterization of an ABC (ATP-binding cassette) transporter encoded by the genes drrA and drrB of Mycobacterium tuberculosis. Biochem J. 2002, 367: 279-285. 10.1042/BJ20020615.View ArticleGoogle Scholar
- Ward A, Reyes CL, Yu J, Roth CB, Chang G: Flexibility in the ABC transporter MsbA: alternating access with a twist. Proc Natl Acad of Sci USA. 2007, 104 (48): 19005-19010. 10.1073/pnas.0709388104.View ArticleGoogle Scholar
- Zou P, McHaourab HS: Alternating access of the putative substrate-binding chamber in the ABC transporter MsbA. J Mol Biol. 2009, 393 (3): 574-585. 10.1016/j.jmb.2009.08.051.View ArticleGoogle Scholar
- Chang G, Roth CB: Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP-binding cassette (ABC) transporters. Science. 2001, 293 (5536): 1793-1800. 10.1126/science.293.5536.1793.View ArticleGoogle Scholar
- Linton KJ: Structure and function of ABC transporters. Physiology (Bethesda). 2007, 22: 122-130. 10.1152/physiol.00046.2006.View ArticleGoogle Scholar
- Linton KJ, Higgins CF: Structure and function of ABC transporters: the ATP switch provides flexible control. PflügersArchiv European Journal of Physiology. 2007, 453 (5): 555-567. 10.1007/s00424-006-0126-x.View ArticleGoogle Scholar
- Grote M, Polyhach Y, Jeschke G, Steinhoff HJ, Schneider E, Bordignon E: Transmembrane signaling in the maltose ABC transporter MalFGK2-E: periplasmic MalF-P2 loop communicates substrate availability to the ATP-bound MalK dimmer. J Biol Chem. 2009, 284 (26): 17521-17526. 10.1074/jbc.M109.006270.View ArticleGoogle Scholar
- Loo TW, Bartlett MC, Clarke DM: The "LSGGQ" motif in each nucleotide-binding domain of human P-glycoprotein is adjacent to the opposing Walker A sequence. J Biol Chem. 2002, 277: 41303-41306. 10.1074/jbc.C200484200.View ArticleGoogle Scholar
- Qiu J, Zhuo Y, Zhu D, Zhou X, Zhang L, Bai L, Deng Z: Overexpression of the ABC transporter AvtAB increases avermectin production in Streptomyces avermitilis. Appl Microbiol Biotechnol. 2011, 92 (2): 337-345. 10.1007/s00253-011-3439-4.View ArticleGoogle Scholar
- Malla S, Niraula NP, Liou KK, Sohng JK: Self-resistance mechanism in Streptomyces peucetius: Overexpression of drrA, drrB and drrC for doxorubicin enhancement. Microbiol Res. 2010, 165 (4): 259-267. 10.1016/j.micres.2009.04.002.View ArticleGoogle Scholar
- McMurry LM, Levy SB: Revised sequence of OtrB (tet347) tetracycline efflux protein from Streptomyces rimosus. Antimicrob Agents Chemother. 1998, 42: 3050-Google Scholar
- Petkovic H, Cullum J, Hranueli D, Hunter IS, Perić CN, Pigac J, Thamchaipenet A, Vujaklija D, Long PF: Genetics of Streptomyces rimosus, the oxytetracycline producer. Microbiol Mol Biol Rev. 2006, 70: 704-728. 10.1128/MMBR.00004-06.View ArticleGoogle Scholar
- Guilfoile PG, Hutchinson R: A bacterial analog of the mdr gene of mammalian tumor cells is present in Streptomyces peucetius, the producer of doxorubicin and daunorubicin. Proceedings of the National Academy of Sciences USA. 1991, 88: 8553-8557. 10.1073/pnas.88.19.8553.View ArticleGoogle Scholar
- Fernandez-Moreno MA, Carbo L, Cuesta T, Vallin C, Malpartida F: A silent ABC transporter isolated from Streptomyces rochei F20 induces multidrug resistance. J Bacteriol. 1998, 180 (16): 4017-4023.Google Scholar
- Zhang H, Pradhan P, Kaur P: The extreme C terminus of the ABC protein DrrA contains unique motifs involved in function and assembly of the DrrAB complex. J Biol Chem. 2010, 285 (49): 38324-38336. 10.1074/jbc.M110.131540.View ArticleGoogle Scholar
- Kaur P, Rao DK, Gandlur SM: Biochemical characterization of domains in the membrane subunit DrrB that interact with the ABC subunit DrrA: identification of a conserved motif. Biochemistry. 2005, 44: 2661-2670. 10.1021/bi048959c.View ArticleGoogle Scholar
- Malla S, Niraula NP, Liou K, Sohng JK: Improvement in doxorubicin productivity by overexpression of regulatory genes in Streptomyces peucetius. Res Microbiol. 2010, 162: 109-117.View ArticleGoogle Scholar
- Smanski MJ, Peterson RM, Rajski SR, Shen B: Engineered Streptomyces platensis Strains that overproduce antibiotics platensimycin and platencin. Antimicrob Agents Chemother. 2009, 53 (4): 1299-1304. 10.1128/AAC.01358-08.View ArticleGoogle Scholar
- Xu D, Kim TJ, Park ZY, Lee SK, Yang SH, Kwon HJ, Suh JW: A DNA-binding factor, ArfA, interacts with the bldH promoter and affects undecylprodigiosin production in Streptomyces lividans. Biochem Biophys Res Commun. 2009, 379 (2): 319-323. 10.1016/j.bbrc.2008.12.052.View ArticleGoogle Scholar
- Yuan LZ, Rouviere PE, Larossa RA, Suh W: Chromosomal promoter replacement of the isoprenoid pathway for enhancing carotenoid production in E. coli. Metab Eng. 2006, 8 (1): 79-90. 10.1016/j.ymben.2005.08.005.View ArticleGoogle Scholar
- Steigedal M, Valla S: The Acinetobacter sp. chnB promoter together with its cognate positive regulator ChnR is an attractive new candidate for metabolic engineering applications in bacteria. Metab Eng. 2008, 10 (12): 121-129.View ArticleGoogle Scholar
- MacNeil DJ, Gewain KM, Ruby CL, Dezeny G, Gibbons PH, MacNeil T: Analysis of Streptomyces avermitilis genes required for avermectin biosynthesis utilizing a novel integration vector. Gene. 1992, 111: 61-68. 10.1016/0378-1119(92)90603-M.View ArticleGoogle Scholar
- Kieser T, Bibb MJ, Buttner MJ, Chater KF, Hopwood DA: Practical Streptomyces genetics. 2000, United Kingdom: John Innes Foundation, NorwichGoogle Scholar
- Wang JY, Yang SS: Morphogenesis, biomass and oxytetracycline production of Streptomyces rimosus in submerged cultivation. annual scientific report of national laboratories of foods and drugs. Depart of Health, Executive Yuan, Taiwan R.O.C. 1996, 14: 68-78.Google Scholar
- Baykov AA, Evtushenko OA, Avaeva SM: A malachite green procedure for orthophosphate determination and its use in alkaline phosphatase-based enzyme immunoassay. Anal Biochem. 1988, 171 (2): 266-270. 10.1016/0003-2697(88)90484-8.View ArticleGoogle Scholar
- Sakamoto K, Margolles A, van Veen HW, Konings WN: Hop resistance in the beer spoilage bacterium Lactobacillus brevis is mediated by the ATP-binding cassette multidrug transporter HorA. J Bacteriol. 2001, 183 (18): 5371-5375. 10.1128/JB.183.18.5371-5375.2001.View ArticleGoogle Scholar
- Bierman M, Logan R, O'Brien K, Seno ET, Rao RN, Schoner BE: Plasmid cloning vectors for the conjugal transfer of DNA from Escherichia coli to Streptomyces spp. Gene. 1992, 116 (1): 43-49. 10.1016/0378-1119(92)90627-2.View ArticleGoogle Scholar
- Yu L, Cao N, Wang L, Xiao C, Guo M, Chu J, Zhuang Y, Zhang S: Oxytetracycline biosynthesis improvement in Streptomyces rimosus following duplication of minimal PKS genes. Enzyme Microb Technol. 2012, 50 (6–7): 318-324.View ArticleGoogle Scholar
- Taylor S, Wakem M, Dijkman G, Alsarraj M, Nguyen M: A practical approach to RT-qPCR-publishing data that conform to the MIQE guidelines. Methods. 2010, 50: S1-S5. 10.1016/j.ymeth.2010.01.005.View ArticleGoogle Scholar
- Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT: The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009, 55 (4): 611-622. 10.1373/clinchem.2008.112797.View ArticleGoogle Scholar
- Li R, Liu G, Xie ZJ, He XH, Chen WQ, Deng ZX, Tan HR: PolY, a transcriptional regulator with ATPase activity, directly activates transcription of polR in polyoxin biosynthesis in Streptomyces cacaoi. Mol Microbiol. 2010, 75 (2): 349-364. 10.1111/j.1365-2958.2009.06968.x.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.